Welcome to our dedicated page for Corvus Pharmaceu SEC filings (Ticker: CRVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Corvus Pharmaceuticals' SEC filings document a clinical-stage biopharmaceutical issuer focused on ITK inhibition and immune modulation. Form 8-K reports furnish operating and financial results, business updates, and clinical disclosures for soquelitinib, including atopic dermatitis and relapsed/refractory peripheral T cell lymphoma program information.
Proxy materials describe annual meeting matters, board composition, committee service, executive compensation, equity awards, and shareholder voting. Registration statements and current reports also record common stock offerings, shelf registration activity, at-the-market sale agreements, underwriting arrangements, and Nasdaq-listed common stock capital-structure disclosures.
Corvus Pharmaceuticals director and 10% owner Peter A. Thompson reported multiple option exercises linked to OrbiMed-affiliated entities. On 01/28/2026, stock options covering 210,000 shares of common stock were exercised at strike prices ranging from $0.965 to $15, resulting in 210,000 shares of common stock reported as directly owned.
An additional 8,609,091 shares of common stock are reported as indirectly owned through OrbiMed Private Investments V, LP and related OrbiMed entities. The filing states that Thompson, OrbiMed Advisors and OrbiMed Capital GP V LLC each disclaim beneficial ownership of these securities except to the extent of any pecuniary interest.
The Vanguard Group reported a passive ownership stake in Corvus Pharmaceuticals common stock. Vanguard disclosed beneficial ownership of 3,873,482 shares, representing 5.18% of the class as of December 31, 2025. Vanguard has shared voting power over 472,993 shares and shared dispositive power over all 3,873,482 shares, with no sole voting or dispositive power.
The shares are held for Vanguard’s investment clients, who are entitled to dividends and sale proceeds, and no single client holds more than 5% of the class. Vanguard also notes an internal realignment effective January 12, 2026, after which certain subsidiaries are expected to report beneficial ownership on a disaggregated basis.
Corvus Pharmaceuticals’ major shareholder OrbiMed filed an ownership update after Corvus completed an underwritten public offering of 7,900,677 common shares at $22.15 per share. Following this offering, OrbiMed Private Investments V, LP beneficially owns 8,609,091 shares, or about 10.3% of Corvus’s common stock, including pre-funded warrants for 1,444,085 shares.
The filing explains that OrbiMed’s ownership percentage fell by more than 1% due to the increase in Corvus’s shares outstanding, not due to share sales. A 45-day lock-up applies to director Peter Thompson and certain other insiders, limiting most share sales and registration demands after the offering.
Corvus Pharmaceuticals entered an underwriting agreement for an underwritten public stock offering of 7,900,677 shares of common stock at a public offering price of $22.15 per share. Underwriters agreed to buy the shares at $20.821 per share and were granted a 30‑day option to purchase an additional 1,185,101 shares, which they exercised in full on January 22, 2026. After underwriting discounts, commissions and estimated expenses and including the option shares, Corvus expects net proceeds of approximately $188.3 million. The company plans to use these funds for working capital and general corporate purposes, including capital expenditures, research and development for its Phase 3 T cell lymphoma and multiple Phase 2 dermatology and asthma trials, as well as sales, marketing and administrative expenses.
Corvus Pharmaceuticals, Inc. is offering 7,900,677 shares of common stock at $22.15 per share in an underwritten public offering on the Nasdaq Global Market. Underwriters also have a 30‑day option to buy up to 1,185,101 additional shares, implying gross proceeds of about $174.999,995.55 and underwriting discounts and commissions of $10,499,999.73, before expenses.
The company expects net proceeds of approximately $163.6 million, or $188.3 million if the option is fully exercised, and plans to use the cash mainly for working capital and research and development, including Phase 3 T cell lymphoma and Phase 2 atopic dermatitis, hidradenitis suppurativa and asthma trials, plus sales, marketing and administrative expenses. Together with existing cash, cash equivalents and marketable securities, Corvus expects to fund operations into the first quarter of 2028.
Corvus recently reported positive Phase 1 cohort 4 data for soquelitinib in moderate to severe atopic dermatitis, showing a 72% mean reduction in EASI at day 56 versus 40% on placebo and higher EASI 75 and IGA 0/1 response rates, including in patients previously treated with systemic therapies. As of December 31, 2025, it preliminarily estimates cash, cash equivalents and marketable securities of about $56.7 million and has suspended its $100 million at‑the‑market program with Jefferies after selling no shares.
Corvus Pharmaceuticals is launching a $150 million primary offering of common stock and pre-funded warrants, plus an underwriters’ option for up to an additional $22.5 million of common stock. The pre-funded warrants are priced at the share offering price minus $0.0001 and are exercisable at $0.0001 per share, subject to ownership caps, and this prospectus also covers the shares issuable upon their exercise. Corvus reports positive Phase 1 data for soquelitinib in moderate to severe atopic dermatitis, with a 72% mean EASI reduction at day 56 versus 40% for placebo in cohort 4 and favorable safety. The company had approximately $56.7 million in cash, cash equivalents and marketable securities as of December 31, 2025 on a preliminary basis, and expects existing cash plus offering proceeds to fund operations into the first quarter of 2028, although it has disclosed substantial doubt about its ability to continue as a going concern without additional capital.
Corvus Pharmaceuticals is launching a $150 million primary offering of common stock and pre-funded warrants, plus an underwriters’ option for up to an additional $22.5 million of common stock. The pre-funded warrants are priced at the share offering price minus $0.0001 and are exercisable at $0.0001 per share, subject to ownership caps, and this prospectus also covers the shares issuable upon their exercise. Corvus reports positive Phase 1 data for soquelitinib in moderate to severe atopic dermatitis, with a 72% mean EASI reduction at day 56 versus 40% for placebo in cohort 4 and favorable safety. The company had approximately $56.7 million in cash, cash equivalents and marketable securities as of December 31, 2025 on a preliminary basis, and expects existing cash plus offering proceeds to fund operations into the first quarter of 2028, although it has disclosed substantial doubt about its ability to continue as a going concern without additional capital.
Corvus Pharmaceuticals, Inc. filed an update explaining that on January 20, 2026 it suspended sales under its Open Market Sale AgreementSM with Jefferies LLC. This at-the-market program had been established under a Form S-3 shelf registration and related August 6, 2024 prospectus supplement to permit sales of up to $100 million of ATM Shares of common stock. Before the suspension, no ATM Shares had been sold, so the full $100 million of ATM Shares remained available. The agreement with Jefferies remains in effect, but the company states it will not sell common stock under this program unless and until it files a new prospectus supplement or registration statement with the SEC.
Corvus Pharmaceuticals, Inc. filed an update explaining that on January 20, 2026 it suspended sales under its Open Market Sale AgreementSM with Jefferies LLC. This at-the-market program had been established under a Form S-3 shelf registration and related August 6, 2024 prospectus supplement to permit sales of up to $100 million of ATM Shares of common stock. Before the suspension, no ATM Shares had been sold, so the full $100 million of ATM Shares remained available. The agreement with Jefferies remains in effect, but the company states it will not sell common stock under this program unless and until it files a new prospectus supplement or registration statement with the SEC.
Corvus Pharmaceuticals reported positive new data from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis. Patients receiving 200 mg twice daily for 56 days showed a mean 70% reduction in EASI scores, compared with 40% for placebo, and 75% achieved EASI 75 versus 20% on placebo. Responses deepened between days 28 and 56, with statistically significant separation at day 56 and activity seen even in patients previously treated with systemic therapies such as dupilumab and JAK inhibitors. Biomarker results support the drug’s ITK inhibition mechanism, indicating immune rebalancing across multiple T cell pathways. Safety in cohort 4 remained favorable, with only Grade 1–2 adverse events and no serious events. Based on these results, the company plans to start a Phase 2 trial in the first quarter of 2026.
Corvus Pharmaceuticals reported positive new data from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis. Patients receiving 200 mg twice daily for 56 days showed a mean 70% reduction in EASI scores, compared with 40% for placebo, and 75% achieved EASI 75 versus 20% on placebo. Responses deepened between days 28 and 56, with statistically significant separation at day 56 and activity seen even in patients previously treated with systemic therapies such as dupilumab and JAK inhibitors. Biomarker results support the drug’s ITK inhibition mechanism, indicating immune rebalancing across multiple T cell pathways. Safety in cohort 4 remained favorable, with only Grade 1–2 adverse events and no serious events. Based on these results, the company plans to start a Phase 2 trial in the first quarter of 2026.
Corvus Pharmaceuticals, Inc. reported an insider equity award to its President, CEO and Director, Richard A. Miller. On 12/04/2025 he was granted a stock option to purchase 1,000,000 shares of Corvus common stock at an exercise price of $8.81 per share.
The option expires on 12/04/2035 and the underlying shares vest in equal monthly installments. Specifically, 1/36th of the shares vest each month starting on December 4, 2025, as long as he continues his service relationship with the company. Following this grant, he directly holds 1,000,000 derivative securities in the form of stock options.
Corvus Pharmaceuticals reported that its Chief Business Officer, Jeffrey Arcara, acquired a stock option covering 100,000 shares of common stock on December 4, 2025. The option has an exercise price of $8.81 per share and is held directly.
The underlying shares vest in equal monthly installments, with 1/36 of the shares vesting each month starting from December 4, 2025, as long as Arcara continues his service with the company. The option expires on December 4, 2035, and following this transaction he beneficially owned 100,000 stock options.